RxDoctor Payments Data

Brendan Sullivan, MD

Cardiovascular Disease · Clifton, NJNPI 1174521140

Payments from drug & device makers

$6,543in general payments, 2019–2025

Across 71 payments — averaging $92.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Novo Nordisk$196
  • Amarin Pharma, Inc.$141
  • Johnson & Johnson$130
  • E.r. Squibb & Sons, L.L.C.$92
  • Merck$80
  • plus $397 from 12 others

What the payments were for

  • Speaking & faculty fees$5,00076%
  • Food & beverage$1,46022%
  • Education$821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,543 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$521,464
Medicare patients
558
Services billed
4,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$289,334
XareltoRivaroxaban97$103,494
JardianceEmpagliflozin38$46,196
OzempicSemaglutide30$29,027
Repatha SureclickEvolocumab19$23,235
VascepaIcosapent Ethyl24$16,766
EntrestoSacubitril/Valsartan17$14,628
MounjaroTirzepatide12$12,497
Pitavastatin Calcium30$12,359
Icosapent Ethyl17$10,834
TrulicityDulaglutide11$10,520
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med115$8,125
Atorvastatin Calcium519$7,983
Carvedilol ErCarvedilol Phosphate17$7,344
Metoprolol Succinate385$6,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$289,334306 claims
Johnson & JohnsonXarelto$130$103,49497 claims
Boehringer IngelheimJardiance$55$46,19638 claims
Novo NordiskOzempic$196$29,02730 claims
Lilly USA, LLCMounjaro, Trulicity$16$23,01723 claims
NovartisEntresto$18$14,62817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →